Search
for
Sort by
Research 91–120 of 1000+
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- 863 Molecular basis of hair follicle donor dominance in androgenetic alopecia and sexual dimorphism of the skin
- LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
- Revisión y avances en tricología
- 700 Oncostatin M is upstream of JAK-STAT signaling during the murine hair cycle
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata
- TREMendous Macrophages Inhibit Hair Growth
- Myeloproliferative disorder associated with alopecia universalis
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata